clarithromycin has been researched along with Myelodysplastic Syndromes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Korekawa, A; Nakajima, K; Nakano, H; Sawamura, D | 1 |
| Inagaki, Y; Ito, T; Kato, T; Ono, Y; Sawa, M | 1 |
| Chin, BS; Choi, HK; Choi, JY; Choi, SH; Han, SH; Jeong, SJ; Kim, CO; Kim, JM; Kim, KM; Kim, MS; Lee, HS; Song, YG | 1 |
1 review(s) available for clarithromycin and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Disseminated Mycobacterium kansasii infection associated with skin lesions: a case report and comprehensive review of the literature.
Topics: Antitubercular Agents; Clarithromycin; Glucocorticoids; Humans; Immunocompromised Host; Isoniazid; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Myelodysplastic Syndromes; Rifampin; Skin Diseases, Bacterial; Sputum; Sweet Syndrome | 2010 |
2 other study(ies) available for clarithromycin and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Clarithromycin for the treatment of pyoderma gangrenosum associated with myelodysplastic syndrome.
Topics: Clarithromycin; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes; Pyoderma Gangrenosum | 2022 |
Disseminated Cutaneous Infection of Mycobacterium colombiense in a Patient with Myelodysplastic Syndrome.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Ethambutol; Humans; Immunocompromised Host; Male; Middle Aged; Mycobacterium; Mycobacterium Infections; Myelodysplastic Syndromes; Rifampin; Treatment Outcome | 2018 |